Topic Hub
7 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 7 of 7 clinical reviews.
A critical appraisal of IMPROVE-IT methodology, enrollment biases, statistical caveats, generalizability gaps, and conflict-of-interest considerations for ezetimibe plus simvastatin in post-ACS patients.
Read clinical reviewDeep-dive into cost-effectiveness analyses from the IMPROVE-IT trial: cost per QALY for ezetimibe-simvastatin, payer coverage shifts after generic entry, and how individual patients should weigh economic value against cardiovascular benefit.
Read clinical reviewLong-term follow-up from the IMPROVE-IT trial reveals durable cardiovascular benefit of ezetimibe plus simvastatin, with no late safety signals and sustained MACE reduction beyond the original study period.
Read clinical reviewDeep-dive into IMPROVE-IT pre-specified and post-hoc subgroup analyses by age, sex, BMI, diabetes status, baseline LDL, and race. Which patients benefited most from ezetimibe added to simvastatin after acute coronary syndrome?
Read clinical reviewA deep-dive into the IMPROVE-IT trial (2015), which tested ezetimibe plus simvastatin versus simvastatin alone in 18,144 post-ACS patients and proved that lowering LDL cholesterol below traditional targets reduces cardiovascular events.
Read clinical reviewA deep-dive into the IMPROVE-IT trial's randomization, blinding, endpoint adjudication, statistical plan, and how each design choice shapes interpretation of ezetimibe-simvastatin results.
Read clinical reviewA deep-dive into the IMPROVE-IT trial (ezetimibe + simvastatin vs simvastatin alone post-ACS) and what its 6.4% relative MACE reduction means for prescribing, guidelines, and patients outside the trial population.
Read clinical review